8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Mar 31, 2026·SEC
Xtant Medical Holdings, Inc.(XTNT)Earnings, Financials & Key Ratios
XTNT•AMEX
14.7× P/E·Price updated Jun 19, 2026
AboutXtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.Show more
- Revenue$134M+14.2%
- EBITDA$13M+259.3%
- Net Income$5M+130.2%
- EPS (Diluted)0.03+125.0%
- Gross Margin62.92%+8.2%
- EBITDA Margin9.34%+239.5%
- Operating Margin5.44%+152.8%
- Net Margin3.71%+126.5%
- ROE10.59%+130.4%
XTNT Key Insights
Xtant Medical Holdings, Inc. (XTNT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 8/9
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 20.2%
- ✓Trading at only 1.3x book value
- ✓Efficient asset utilization: 1.4x turnover
✗Weaknesses
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Shares diluted 12.3% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when XTNT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XTNT Price & Volume
Xtant Medical Holdings, Inc. (XTNT) stock price & volume — 10-year historical chart
Loading chart...
XTNT Growth Metrics
Xtant Medical Holdings, Inc. (XTNT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.48%
5 Years20.22%
3 Years32.2%
TTM-0.32%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM115.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM114.13%
Return on Capital
10 Years-21.34%
5 Years-10.53%
3 Years-8.14%
Last Year11.21%
XTNT Recent Earnings
Xtant Medical Holdings, Inc. (XTNT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.02-33.3%
$0.01
Rev
$21M+3.6%
$20M
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.00+108.2%
$0.00
Rev
$32M+5.2%
$31M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.01+290.5%
$0.01
Rev
$33M+8.1%
$31M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.02+300.0%
$0.01
Rev
$35M+13.5%
$31M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.02vs $0.01-33.3% | $21Mvs $20M+3.6% |
| Q2 2026 | Mar 31, 2026 | $0.00vs $0.00+108.2% | $32Mvs $31M+5.2% |
| Q4 2025 | Nov 10, 2025 | $0.01vs $0.01+290.5% | $33Mvs $31M+8.1% |
| Q3 2025 | Aug 12, 2025 | $0.02vs $0.01+300.0% | $35Mvs $31M+13.5% |
Based on last 12 quarters of dataView full earnings history →
XTNT Peer Comparison
Xtant Medical Holdings, Inc. (XTNT) competitors in Orthopedics, spine, and sports medicine — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATEC | 1.33B | 8.81 | -9.18 | 24.95% | -21.07% | -443.09% | 17.21 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 OSPN | 505.8M | 13.50 | 7.11 | 0% | 28.47% | 27.31% | 0.02 | |
 GMED | 10.69B | 79.23 | 20.21 | 16.65% | 18.92% | 13.04% | 0.03 | |
 OSIS | 3.67B | 222.78 | 25.58 | 11.33% | 8.42% | 16.74% | 0.72 | |
 IART | 1.37B | 17.58 | -2.61 | 1.53% | -30.15% | -47.65% | 1.95 | |
 AHCO | 1.31B | 9.65 | -18.56 | -0.49% | -2.78% | -5.09% | 1.25 | |
 ZBH | 17.22B | 87.97 | 24.78 | 7.2% | 9.05% | 5.77% | 0.59 |
Compare XTNT vs Peers
Xtant Medical Holdings, Inc. (XTNT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XTNT Income Statement
Xtant Medical Holdings, Inc. (XTNT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 82.61M | 72.2M | 64.68M | 53.34M | 55.26M | 57.97M | 91.3M | 117.27M | 133.93M | 121.91M |
Revenue Growth % | -8.21% | -12.6% | -10.42% | -17.54% | 3.61% | 4.9% | 57.5% | 28.44% | 14.21% | -0.32% |
Cost of Goods Sold | 32.51M | 28.72M | 22.17M | 18.95M | 22.77M | 25.83M | 35.84M | 49.05M | 49.65M | 45.91M |
COGS % of Revenue | 39.35% | 39.77% | 34.27% | 35.52% | 41.21% | 44.56% | 39.25% | 41.83% | 37.08% | - |
Gross Profit | 50.1M▲ 0% | 43.49M▼ 13.2% | 42.52M▼ 2.2% | 34.39M▼ 19.1% | 32.49M▼ 5.5% | 32.14M▼ 1.1% | 55.47M▲ 72.6% | 68.22M▲ 23.0% | 84.27M▲ 23.5% | 76M▲ 0% |
Gross Margin % | 60.65% | 60.23% | 65.73% | 64.48% | 58.79% | 55.44% | 60.75% | 58.17% | 62.92% | 62.34% |
Gross Profit Growth % | -19.57% | -13.2% | -2.23% | -19.11% | -5.53% | -1.09% | 72.6% | 22.98% | 23.54% | - |
Operating Expenses | 63.77M | 50.88M | 44.77M | 35.14M | 36.34M | 38.89M | 65.63M | 80.29M | 76.99M | 72.7M |
OpEx % of Revenue | 77.19% | 70.47% | 69.21% | 65.89% | 65.77% | 67.09% | 71.88% | 68.47% | 57.49% | - |
Selling, General & Admin | 55.84M | 45.06M | 43.78M | 34.49M | 35.47M | 37.98M | 64.29M | 77.91M | 74.89M | 70.61M |
SG&A % of Revenue | 67.6% | 62.41% | 67.68% | 64.66% | 64.19% | 65.51% | 70.41% | 66.43% | 55.92% | - |
Research & Development | 2.44M | 1.7M | 932K | 657K | 870K | 915K | 1.34M | 2.38M | 2.1M | 2.09M |
R&D % of Revenue | 2.95% | 2.36% | 1.44% | 1.23% | 1.57% | 1.58% | 1.46% | 2.03% | 1.57% | - |
Other Operating Expenses | -74.71K | 3K | 58K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -37.83M▲ 0% | -60.08M▼ 58.8% | -2.35M▲ 96.1% | -751K▲ 68.1% | -3.85M▼ 413.2% | -6.75M▼ 75.3% | -10.16M▼ 50.4% | -12.07M▼ 18.9% | 7.28M▲ 160.3% | 3.3M▲ 0% |
Operating Margin % | -45.8% | -83.21% | -3.64% | -1.41% | -6.97% | -11.65% | -11.13% | -10.3% | 5.44% | 2.71% |
Operating Income Growth % | -401.43% | -58.79% | 96.08% | 68.1% | -413.18% | -75.27% | -50.38% | -18.86% | 160.33% | - |
EBITDA | -29.44M | -54.34M | 847K | 1.33M | -2.51M | -5.46M | -6.98M | -7.85M | 12.51M | 7.98M |
EBITDA Margin % | -35.64% | -75.26% | 1.31% | 2.49% | -4.55% | -9.42% | -7.65% | -6.69% | 9.34% | 6.55% |
EBITDA Growth % | -9603.7% | -84.57% | 101.56% | 56.79% | -289.23% | -117.23% | -27.94% | -12.4% | 259.32% | 345.64% |
D&A (Non-Cash Add-back) | 8.39M | 5.74M | 3.2M | 2.08M | 1.34M | 1.3M | 3.17M | 4.22M | 5.22M | 4.68M |
EBIT | -37.71M | -59.95M | -2.35M | -751K | -3.85M | -6.72M | 1.9M | -12.1M | 10.67M | 6.67M |
Net Interest Income | -14.71M | -10.14M | -5.77M | -5.98M | -995K | -1.66M | -2.79M | -4.16M | -3.58M | -2.91M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 31K | 149K | 0 | 94K | 313K |
Interest Expense | 14.7M | 10.14M | 5.77M | 5.98M | 995K | 1.69M | 2.94M | 4.16M | 3.67M | 3.23M |
Other Income/Expense | -14.58M | -10.02M | -5.87M | -5.98M | -995K | -1.66M | 9.12M | -4.19M | -283K | 608K |
Pretax Income | -52.41M▲ 0% | -70.1M▼ 33.7% | -8.12M▲ 88.4% | -6.73M▲ 17.2% | -4.85M▲ 27.9% | -8.42M▼ 73.6% | -1.04M▲ 87.7% | -16.26M▼ 1468.2% | 7M▲ 143.1% | 3.91M▲ 0% |
Pretax Margin % | -63.44% | -97.09% | -12.56% | -12.61% | -8.77% | -14.52% | -1.14% | -13.87% | 5.23% | 3.2% |
Income Tax | 0 | 124K | 98K | 296K | 0 | 69K | -1.7M | 187K | 2.03M | 2.08M |
Effective Tax Rate % | 0% | -0.18% | -1.21% | -4.4% | 0% | -0.82% | 163.65% | -1.15% | 28.97% | 53.25% |
Net Income | -52.41M▲ 0% | -70.1M▼ 33.7% | -8.22M▲ 88.3% | -7.02M▲ 14.6% | -4.85M▲ 31.0% | -8.48M▼ 75.0% | 660K▲ 107.8% | -16.45M▼ 2592.3% | 4.97M▲ 130.2% | 1.83M▲ 0% |
Net Margin % | -63.44% | -97.09% | -12.71% | -13.17% | -8.77% | -14.64% | 0.72% | -14.03% | 3.71% | 1.5% |
Net Income Growth % | -168.86% | -33.75% | 88.27% | 14.57% | 30.96% | -74.98% | 107.78% | -2592.27% | 130.23% | 115.23% |
Net Income (Continuing) | -52.41M | -70.1M | -8.22M | -7.02M | -4.85M | -8.48M | 660K | -16.45M | 4.97M | 1.83M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -34.51▲ 0% | -5.93▲ 82.8% | -0.62▲ 89.5% | -0.25▲ 59.7% | -0.06▲ 77.3% | -0.09▼ 59.1% | 0.01▲ 105.8% | -0.12▼ 2407.7% | 0.03▲ 125.0% | 0.01▲ 0% |
EPS Growth % | -88.37% | 82.82% | 89.54% | 59.68% | 77.32% | -59.08% | 105.77% | - | 125% | 114.13% |
EPS (Basic) | -34.76 | -5.97 | -0.62 | -0.25 | -0.06 | -0.09 | 0.01 | -0.12 | 0.04 | - |
Diluted Shares Outstanding | 1.52M | 11.83M | 13.16M | 28.5M | 85.46M | 94.09M | 126.79M | 133.67M | 150.04M | 150.46M |
Basic Shares Outstanding | 1.51M | 11.74M | 13.16M | 28.5M | 85.46M | 94.09M | 119.09M | 133.67M | 139.53M | 139.83M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
XTNT Balance Sheet
Xtant Medical Holdings, Inc. (XTNT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 39.5M | 34.68M | 32.25M | 31.36M | 44.33M | 49.32M | 64.87M | 67.12M | 78.25M | 62.62M |
Cash & Short-Term Investments | 2.86M | 6.8M | 5.24M | 2.34M | 18.24M | 20.3M | 5.71M | 6.2M | 17.05M | 12.16M |
Cash Only | 2.86M | 6.8M | 5.24M | 2.34M | 18.24M | 20.3M | 5.71M | 6.2M | 17.05M | 12.16M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 12.71M | 9.99M | 10.12M | 6.88M | 7.15M | 10.85M | 20.73M | 20.66M | 17.8M | 17.18M |
Days Sales Outstanding | 56.18 | 50.5 | 57.13 | 47.08 | 47.25 | 68.34 | 82.88 | 64.31 | 48.52 | 65.46 |
Inventory | 22.23M | 17.3M | 16.1M | 21.41M | 17.95M | 17.29M | 36.88M | 38.63M | 30.26M | 31.88M |
Days Inventory Outstanding | 249.56 | 219.9 | 265.13 | 412.45 | 287.62 | 244.23 | 375.68 | 287.48 | 222.46 | 284.24 |
Other Current Assets | 0 | 0 | 0 | 0 | 144K | 882K | 1.54M | 1.62M | 13.13M | 1.4M |
Total Non-Current Assets | 66.2M | 11.74M | 10.91M | 10.1M | 10.36M | 10.91M | 27.74M | 26.72M | 15.9M | 15.38M |
Property, Plant & Equipment | 9.91M | 7.17M | 6.79M | 6.04M | 6.47M | 7.17M | 10.21M | 10.96M | 9.39M | 8.9M |
Fixed Asset Turnover | 8.33x | 10.06x | 9.52x | 8.84x | 8.54x | 8.09x | 8.94x | 10.70x | 14.26x | 10.84x |
Goodwill | 41.53M | 3.21M | 3.21M | 3.21M | 3.21M | 3.21M | 7.3M | 7.3M | 6.07M | 6.07M |
Intangible Assets | 13.83M | 573K | 515K | 457K | 400K | 344K | 10.09M | 8.36M | 299K | 275K |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 925.25K | 793K | 394K | 402K | 287K | 197K | 141K | 103K | 133K | 131K |
Total Assets | 105.7M▲ 0% | 46.42M▼ 56.1% | 43.16M▼ 7.0% | 41.47M▼ 3.9% | 54.69M▲ 31.9% | 60.23M▲ 10.1% | 92.61M▲ 53.8% | 93.84M▲ 1.3% | 94.14M▲ 0.3% | 78M▲ 0% |
Asset Turnover | 0.78x | 1.56x | 1.50x | 1.29x | 1.01x | 0.96x | 0.99x | 1.25x | 1.42x | 1.28x |
Asset Growth % | -26.65% | -56.08% | -7.04% | -3.91% | 31.9% | 10.12% | 53.77% | 1.32% | 0.33% | -2.49% |
Total Current Liabilities | 25.82M | 12.05M | 9.39M | 25.65M | 11.08M | 15.22M | 22.99M | 28.58M | 29.48M | 18.77M |
Accounts Payable | 9.32M | 6.46M | 2.19M | 2.29M | 2.62M | 3.49M | 7.05M | 7.92M | 3.84M | 5.49M |
Days Payables Outstanding | 104.59 | 82.17 | 36.03 | 44.1 | 41.91 | 49.31 | 71.85 | 58.92 | 28.26 | 46.53 |
Short-Term Debt | 365.48K | 426K | 570K | 16.8M | 3.62M | 5.71M | 4.62M | 12.12M | 14.36M | 4.81M |
Deferred Revenue (Current) | 16.01M | 5.15M | 6.63M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | -234.68K | 1.4M | -4.46M | 4.71M | 3.18M | 4.46M | 0 | 5.57M | 0 | 407K |
Current Ratio | 1.53x | 2.88x | 3.43x | 1.22x | 4.00x | 3.24x | 2.82x | 2.35x | 2.65x | 3.34x |
Quick Ratio | 0.67x | 1.44x | 1.72x | 0.39x | 2.38x | 2.10x | 1.22x | 1.00x | 1.63x | 1.64x |
Cash Conversion Cycle | 201.14 | 188.23 | 286.23 | 415.43 | 292.96 | 263.26 | 386.71 | 292.87 | 242.72 | 303.16 |
Total Non-Current Liabilities | 138.59M | 78.14M | 77.97M | 1.3M | 12.73M | 10.84M | 18.27M | 22.29M | 13.71M | 10.63M |
Long-Term Debt | 137.96M | 77.94M | 76.24M | 0 | 11.79M | 9.69M | 17.17M | 22.04M | 11.03M | 8.1M |
Capital Lease Obligations | 624K | 204K | 1.73M | 1.3M | 945K | 1.15M | 875K | 213K | 2.68M | 10.22M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 21K | 42K | 5K | 59K |
Other Non-Current Liabilities | -221 | 0 | 0 | 0 | 0 | 0 | 210K | 0 | 0 | 5K |
Total Liabilities | 164.4M | 90.19M | 87.36M | 26.95M | 23.81M | 26.06M | 41.26M | 50.87M | 43.19M | 29.4M |
Total Debt | 138.95M | 78.57M | 78.54M | 18.54M | 16.84M | 17.07M | 23.56M | 35.14M | 28.72M | 15.44M |
Net Debt | 136.1M | 71.77M | 73.3M | 16.2M | -1.4M | -3.23M | 17.84M | 28.94M | 11.66M | 3.28M |
Debt / Equity | - | - | - | 1.28x | 0.55x | 0.50x | 0.46x | 0.82x | 0.56x | 0.32x |
Debt / EBITDA | - | - | 92.73x | 13.96x | - | - | - | - | 2.30x | 1.93x |
Net Debt / EBITDA | - | - | 86.54x | 12.20x | - | - | - | - | 0.93x | 0.41x |
Interest Coverage | -2.56x | -5.91x | -0.41x | -0.13x | -3.87x | -3.97x | 0.65x | -2.91x | 2.91x | 2.07x |
Total Equity | -58.7M▲ 0% | -43.77M▲ 25.4% | -44.2M▼ 1.0% | 14.51M▲ 132.8% | 30.88M▲ 112.8% | 34.17M▲ 10.6% | 51.35M▲ 50.3% | 42.96M▼ 16.3% | 50.95M▲ 18.6% | 48.6M▲ 0% |
Equity Growth % | -729.87% | 25.43% | -0.99% | 132.83% | 112.78% | 10.65% | 50.27% | -16.33% | 18.6% | 47.32% |
Book Value per Share | -38.65 | -3.70 | -3.36 | 0.51 | 0.36 | 0.36 | 0.40 | 0.32 | 0.34 | 0.32 |
Total Shareholders' Equity | -58.7M | -43.77M | -44.2M | 14.51M | 30.88M | 34.17M | 51.35M | 42.96M | 50.95M | 48.6M |
Common Stock | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -144.95M | -215.04M | -223.27M | -230.34M | -235.19M | -243.67M | -243.01M | -259.46M | -254.49M | -257.57M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -11.29M | -12.91M | 0 | 0 | 0 | 0 | 29K | -316K | 0 | -1K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XTNT Cash Flow Statement
Xtant Medical Holdings, Inc. (XTNT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -543.18K | 1.21M | -413K | -731K | 439K | -5.34M | -9.52M | -11.9M | 12.55M | 9.15M |
Operating CF Margin % | -0.66% | 1.68% | -0.64% | -1.37% | 0.79% | -9.21% | -10.42% | -10.14% | 9.37% | - |
Operating CF Growth % | 96.23% | 323.13% | -134.08% | -77% | 160.05% | -1316.63% | -78.15% | -25.02% | 205.46% | 937.14% |
Net Income | -52.41M | -70.1M | -8.22M | -7.02M | -4.85M | -8.48M | 660K | -16.45M | 4.97M | 1.83M |
Depreciation & Amortization | 8.41M | 6.59M | 3.14M | 2.08M | 1.33M | 1.29M | 3.17M | 4.22M | 5.22M | 4.68M |
Stock-Based Compensation | 211.81K | 694K | 515K | 1.08M | 2.21M | 2.46M | 2.74M | 4.12M | 2.89M | 2.24M |
Deferred Taxes | 25.26M | 53.25M | 958K | 0 | 0 | 0 | -1.9M | 21K | 0 | 0 |
Other Non-Cash Items | 14.68M | 9.85M | 5.75M | 6.4M | 954K | 2.2M | -10.55M | 1.54M | 2.5M | 3.46M |
Working Capital Changes | 3.3M | 931K | -2.55M | -3.27M | 793K | -2.81M | -3.63M | -5.35M | -3.05M | -3.05M |
Change in Receivables | 4.75M | 2.54M | -647K | 2.89M | -319K | -3.94M | -8.74M | -755K | -591K | 2.97M |
Change in Inventory | 2.12M | 40K | 692K | -5.79M | 2.62M | -1.15M | -1.89M | -2.49M | -2M | -3.08M |
Change in Payables | -1.64M | -3.01M | -4.28M | 101K | -332K | 875K | 2.98M | 1.03M | -3.12M | -586K |
Cash from Investing | -1.61M | -367K | -544K | -1.3M | -1.89M | -1.56M | -24.78M | -3.73M | 7.9M | 19.26M |
Capital Expenditures | -1.64M | -624K | -879K | -1.54M | -2.12M | -1.76M | -1.46M | -4.11M | -2.38M | -1.39M |
CapEx % of Revenue | 1.99% | 0.86% | 1.36% | 2.9% | 3.83% | 3.04% | 1.59% | 3.51% | 1.78% | 1.14% |
Acquisitions | 32.5K | 257K | 335K | 0 | 0 | 0 | -23.5M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 32.5K | 257K | 0 | 241K | 225K | 205K | 175K | 383K | 10.28M | 20.65M |
Cash from Financing | 2.43M | 3.1M | -603K | -861K | 17.5M | 9.02M | 19.69M | 16.07M | -9.57M | -21.93M |
Debt Issued (Net) | 2.25M | -359K | -455K | -471K | -592K | -291K | 6.18M | 12.43M | -9.33M | -21.72M |
Equity Issued (Net) | 178K | 6.81M | 0 | 620K | 18.43M | 9.31M | 14.01M | 4.46M | -65K | -120K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -65K | -120K |
Other Financing | 455 | -3.36M | -148K | -1.01M | -337K | 0 | -500K | -816K | -175K | -87K |
Net Change in Cash | 277.69K▲ 0% | 3.94M▲ 1319.2% | -1.56M▼ 139.6% | -2.9M▼ 85.6% | 16.05M▲ 654.1% | 2.12M▼ 86.8% | -14.58M▼ 787.9% | 298K▲ 102.0% | 11.11M▲ 3627.2% | 6.72M▲ 0% |
Free Cash Flow | -2.18M▲ 0% | 588K▲ 126.9% | -1.29M▼ 319.7% | -2.28M▼ 76.2% | -1.68M▲ 26.4% | -7.11M▼ 323.9% | -10.97M▼ 54.4% | -16.01M▼ 45.9% | 10.16M▲ 163.5% | 7.77M▲ 0% |
FCF Margin % | -2.64% | 0.81% | -2% | -4.27% | -3.03% | -12.26% | -12.02% | -13.65% | 7.59% | 6.37% |
FCF Growth % | 89.21% | 126.92% | -319.73% | -76.16% | 26.36% | -323.93% | -54.41% | -45.92% | 163.49% | 182.7% |
FCF per Share | -1.44 | 0.05 | -0.10 | -0.08 | -0.02 | -0.08 | -0.09 | -0.12 | 0.07 | 0.05 |
FCF Conversion (FCF/Net Income) | 0.01x | -0.02x | 0.05x | 0.10x | -0.09x | 0.63x | -14.42x | 0.72x | 2.52x | 4.25x |
Interest Paid | 0 | 0 | 0 | 0 | 846K | 1.45M | 2.55M | 3.64M | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XTNT Key Ratios
Xtant Medical Holdings, Inc. (XTNT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | -48.39% | -21.36% | -26.09% | 1.54% | -34.88% | 10.59% | 3.68% |
Return on Invested Capital (ROIC) | -28.59% | -85.5% | -6.18% | -1.88% | -9.6% | -16.77% | -15.22% | -12.84% | 8.12% | 3.72% |
Gross Margin | 60.65% | 60.23% | 65.73% | 64.48% | 58.79% | 55.44% | 60.75% | 58.17% | 62.92% | 62.34% |
Net Margin | -63.44% | -97.09% | -12.71% | -13.17% | -8.77% | -14.64% | 0.72% | -14.03% | 3.71% | 1.5% |
Debt / Equity | - | - | - | 1.28x | 0.55x | 0.50x | 0.46x | 0.82x | 0.56x | 0.32x |
Interest Coverage | -2.56x | -5.91x | -0.41x | -0.13x | -3.87x | -3.97x | 0.65x | -2.91x | 2.91x | 2.07x |
FCF Conversion | 0.01x | -0.02x | 0.05x | 0.10x | -0.09x | 0.63x | -14.42x | 0.72x | 2.52x | 4.25x |
Revenue Growth | -8.21% | -12.6% | -10.42% | -17.54% | 3.61% | 4.9% | 57.5% | 28.44% | 14.21% | -0.32% |
Related:XTNT Dividend History·XTNT Revenue History·XTNT Price History·XTNT P/E History·XTNT Financial Ratios·XTNT Institutional Holders
XTNT SEC Filings & Documents
Xtant Medical Holdings, Inc. (XTNT) SEC filings — annual & quarterly reports (10-K, 10-Q)
XTNT Frequently Asked Questions
Xtant Medical Holdings, Inc. (XTNT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Xtant Medical Holdings, Inc. (XTNT) reported $121.9M in revenue for fiscal year 2025. This represents a 26446% increase from $0.5M in 2008.
Xtant Medical Holdings, Inc. (XTNT) grew revenue by 14.2% over the past year. This is steady growth.
Yes, Xtant Medical Holdings, Inc. (XTNT) is profitable, generating $1.8M in net income for fiscal year 2025 (3.7% net margin).
Dividend & Returns
Xtant Medical Holdings, Inc. (XTNT) has a return on equity (ROE) of 10.6%. This is reasonable for most industries.
Xtant Medical Holdings, Inc. (XTNT) generated $7.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.